Name: 9th Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference - West Coast Edition
Start: 2024-02-08
End: 2024-02-09
Location: Double Tree by Hilton, San Diego - Mission Valley | 7450 Hazard Centre Drive San Diego, CA

EVENT OVERVIEW

Leveraging next gen technologies beyond conventional biomarker drug discovery!

MarketsandMarkets bring to you the 9th Annual Biomarker and CDx Conference - West Coast Edition scheduled to be held on 8th - 9th February 2024 in San Diego, USA. This event will have an introduction to turning biomarkers into companion diagnostics.

30+ experts from academia and industry will be presenting their current work in Biomarkers, Latest updates on regulatory guidelines and approvals, Cancer biomarker validation for clinical application, Biomarkers and Personalized Medicine, Impact of Big data in translational biomarker research and Future of Companion Diagnostics

Opportunity to develop long-lasting business relationships and networking opportunities with researchers, scientists, clinicians, academicians and professionals from Pharmaceutical companies, Bio-pharma companies, Universities, and Research institutes.

Over 20 presentations, round-tables, and panel discussions focused on the key opportunities and challenges in biomarker research, from precision medicine and companion diagnostics through to digital biomarkers and clinical trials.

The Expert Panel will take you through their presentations which will include problems, solutions and services in the Clinical Applications of Biomarkers in Immuno-Oncology, Neurology and Inflammatory Diseases. Attendees would evidence the examples and the case studies which will help in creating the revenue. The keynote presentations would also help the attendees understand the issues related to clinical translation of biomarkers.

Commercialization of CDx
Proteomics and Genomics based Biomarkers
Biomarker Drug Discovery and Assay Development
Multiplex Companion Diagnostics and Regulatory Guidelines
Design of clinical trials in CDx
Digital Biomarkers, Predictive Biomarkers, Precision Medicine and Big Data
Clinical Applications of Biomarkers in Immuno-Oncology, Neurology and Inflammatory Diseases

Researchers, scientists, clinicians, academicians and professionals from Pharmaceutical companies, Bio-pharma companies & Universities and Research institutes working in:

Biomarker discovery/development
Translational research
Clinical Biomarker
Biomarkers in IO and Neurological disorders
Imaging Biomarkers
Pathology
Companion Diagnostics
Biomarker Imaging
Proteomics Biomarkers
Experimental Medicine
Data Science
Biomarkers in Clinical Discovery
Immuno-oncology/Neuroscience Drug Discovery
Diagnostic Biomarkers development
Personalized Medicine
Immunology Biomarkers

CONFERENCE AGENDA

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 08:55
Opening Remarks from the Chairperson Jim Kean, Chief Executive Officer, Molecular You	08:55 - 09:00
BIOMARKER DRUG DISCOVERY AND ASSAY VALIDATION
Keynote Presentation :Enhanced Biomarker Discovery and Validation Using TMT® Proteomics Ian Pike, Chief Scientific Officer, Proteome Sciences PLC	09:00 - 09:30
Spatial Analysis in Ulcerative Colitis and Crohn’s Disease Jiangwei Zhang, Senior Principal Scientist, Bristol Myers Squibb	09:30 - 10:00
Development of Methylation and Mutation Panel for Colorectal Cancer Collin Hudzik, Scientist, EpigenDx	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
Next Gen Proteomics identified protein signatures for early pan cancer detection and stratification Kathy Nevola, Data Scientist, Olink	11:15 - 11:45
Flow cytometry for biomarker development, clinical trial assays, MRD, and CDx Scott J. Bornheimer, Associate Director, Medical & Scientific Affairs, BD Biosciences	11:45 - 12:15
AI and Multimoodal Biomarkers for Personalized Pain Medicine Carl Saab, Professor, Innovation Lead Digital Health, Cleveland Clinic	12:15 - 12:45
Identification of cancer cell surface target for antibody drug conjugate development. Ginette Serrero, CEO, Precision Antibody, A&G Pharmaceutical, Inc. \| Precision Antibody	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
Role of biomarkers in personalized medicine Identifying Variants Associated with Creatinine and Cystatin C Serum Levels in the Top 1% of the Population Provides Insight into the Genetic Architecture of Kidney Function and Chronic Kidney Disease. Matteo D’Antonio, Assistant Professor, University of California, San Diego	14:15 - 14:45
Innovative oncology liquid biopsy testing in global markets, from lab testing to CDx Myles A. Walsh, Director of Business Development, Predicine	14:45 - 15:15
Microbial Marvels: Unleashing Targeted Drug Discovery with Pragma Bios Innovative Approach to Disease-Associated Small Molecules and Novel Biomarkers Kareem Barghouti, CEO, Pragma Bio	15:15 - 15:45
Afternoon Refreshments and Poster Presentation \| One-to-One Networking Meetings	15:45 - 16:30
AI-powered multi-omic health analytics Jim Kean, Chief Executive Officer, Molecular You	16:30 - 17:00
Closing Remarks from the Chairperson Jim Kean, Chief Executive Officer, Molecular You	17:00 - 17:30
Drinks Reception & Networking	17:30 - 17:30
End of Day 1	17:30 - 17:30

Registration	08:15 - 09:00
Welcome note from MarketsandMarkets	09:00 - 09:05
Opening Remarks from the Chairperson Jim Kean, Chief Executive Officer, Molecular You	09:05 - 09:10
FROM BIOMARKERS TO CDX: STRATEGIES TO ACCELERATE CDX DEVELOPMENT AND COMMERCIALIZATION
Keynote Presentation Bringing AI to Companion Diagnostics Ken Bloom , Head of Pathology, Nucleai	09:10 - 09:45
The crucial role of biospecimen management in precision medicine Ayat Alsaraby, Sr. Manager, Clinical Biomarker, Repare Therapeutics	09:45 - 10:20
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:20 - 11:05
Opportunities for biomarker development in neuroscience Pablo Lapuerta, Chief Executive Officer, 4M Therapeutics Inc.	11:05 - 11:40
Identifying underlying mechanisms of neurological conditions with multi-omic biomarker analysis Rob Fraser, Chief Scientific Officer, Molecular You	11:40 - 12:15
Panel Discussion: Biomarker Revolution: Enhancing Patient Care Across Specialties Nicole Miller, Vice President, Molecular Diagnostics Global Medical Affairs, Ultragenyx Ken Bloom , Head of Pathology, Nucleai Julius Goepp, CEO, Evimero Pablo Lapuerta, Chief Executive Officer, 4M Therapeutics Inc.	12:15 - 13:00
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:00 - 13:30
End of the conference	13:30 - 13:30

Collin Hudzik

Scientist, EpigenDx

Rob Fraser

Chief Scientific Officer, Molecular You

Ken Bloom

Head of Pathology, Nucleai

Ian Pike

Chief Scientific Officer, Proteome Sciences PLC

Arvind Rao

Associate Professor of Computational Medicine and Bioinformatics, Department of Computational Medicine and Bioinformatics, University of Michigan Ann Arbor